PureTech Health has obtained approval from the US Food and Drug Administration (FDA) for KarXT to treat schizophrenia in ...

Medidata is a winner in the Innovation, and Product Launches categories in the 2024 Pharmaceutical Technology Excellence ...

LEO Pharma has submitted a New Drug Application (NDA) to China's National Medical Products Administration for Enstilar, ...

SK pharmteco, a contract development and manufacturing organisation, has announced an investment of $260m to expand its small ...

The MediLedger Project utilises blockchain technology to tackle counterfeit drugs. The project uses blockchain to track and ...

The US Food and Drug Administration (FDA) has announced the approval of Sanofi and Regeneron’s interleukin (IL)-4 and IL-13 ...

Biocon has entered a partnership with Tabuk for the commercialisation of glucagon-like peptide-1 (GLP-1) products in the ...

The FDA has approved the first treatment for schizophrenia that targets cholinergic receptors rather than dopamine receptors.

Pfizer has announced the withdrawal of all lots of OXBRYTA approved for treating sickle cell disease (SCD) from worldwide ...

The EC has granted marketing authorisation to LEO Pharma’s Anzupgo cream for treating adults with moderate to severe chronic ...

Coverage for its long-acting insulin, Levamir, dropped from 90% to about 35% when the company dropped its list price by 65%.

The US FDA placed a full clinical hold on two diabetes trials for Biomea’s menin inhibitor after reports of liver toxicity.